Masayuki Imamura

Kansai Electric Power Hospital — Japan

Medicine · Health Sciences

71h-index17.0kcitations493works1.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Neuroendocrine Tumor Research Advances(128), Pancreatic and Hepatic Oncology Research(101), Lung Cancer Research Studies(64), Neuroblastoma Research and Treatments(40), Pancreatic function and diabetes(35)

Publications491 total

GLP- 1R status using validated monoclonal antibody in 689 cases of neuroendocrine neoplasm and its correlation with somatostatin receptor scintigraphy, insulin production, and histological grades
Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin·2025· 2 citedOpen Access
Novel Control System for Blood Glucose Using a Model Predictive Method
2024
MicroRNAs associated with postoperative outcomes in patients with limited stage neuroendocrine carcinoma of the esophagus
Oncology Letters·2023· 1 citedOpen Access
Supplementary Figure Legend from Rb Loss and <i>KRAS</i> Mutation Are Predictors of the Response to Platinum-Based Chemotherapy in Pancreatic Neuroendocrine Neoplasm with Grade 3: A Japanese Multicenter Pancreatic NEN-G3 Study
2023Open Access
Table S3 from Rb Loss and <i>KRAS</i> Mutation Are Predictors of the Response to Platinum-Based Chemotherapy in Pancreatic Neuroendocrine Neoplasm with Grade 3: A Japanese Multicenter Pancreatic NEN-G3 Study
2023Open Access
Table S3 from Rb Loss and <i>KRAS</i> Mutation Are Predictors of the Response to Platinum-Based Chemotherapy in Pancreatic Neuroendocrine Neoplasm with Grade 3: A Japanese Multicenter Pancreatic NEN-G3 Study
2023Open Access
Data from Rb Loss and <i>KRAS</i> Mutation Are Predictors of the Response to Platinum-Based Chemotherapy in Pancreatic Neuroendocrine Neoplasm with Grade 3: A Japanese Multicenter Pancreatic NEN-G3 Study
2023Open Access
FigureS1 from Rb Loss and <i>KRAS</i> Mutation Are Predictors of the Response to Platinum-Based Chemotherapy in Pancreatic Neuroendocrine Neoplasm with Grade 3: A Japanese Multicenter Pancreatic NEN-G3 Study
2023Open Access
Table S2 from Rb Loss and <i>KRAS</i> Mutation Are Predictors of the Response to Platinum-Based Chemotherapy in Pancreatic Neuroendocrine Neoplasm with Grade 3: A Japanese Multicenter Pancreatic NEN-G3 Study
2023Open Access
Table S1 from Rb Loss and <i>KRAS</i> Mutation Are Predictors of the Response to Platinum-Based Chemotherapy in Pancreatic Neuroendocrine Neoplasm with Grade 3: A Japanese Multicenter Pancreatic NEN-G3 Study
2023Open Access
Table S1 from Rb Loss and <i>KRAS</i> Mutation Are Predictors of the Response to Platinum-Based Chemotherapy in Pancreatic Neuroendocrine Neoplasm with Grade 3: A Japanese Multicenter Pancreatic NEN-G3 Study
2023Open Access
Table S2 from Rb Loss and <i>KRAS</i> Mutation Are Predictors of the Response to Platinum-Based Chemotherapy in Pancreatic Neuroendocrine Neoplasm with Grade 3: A Japanese Multicenter Pancreatic NEN-G3 Study
2023Open Access
Data from Rb Loss and <i>KRAS</i> Mutation Are Predictors of the Response to Platinum-Based Chemotherapy in Pancreatic Neuroendocrine Neoplasm with Grade 3: A Japanese Multicenter Pancreatic NEN-G3 Study
2023Open Access
FigureS1 from Rb Loss and <i>KRAS</i> Mutation Are Predictors of the Response to Platinum-Based Chemotherapy in Pancreatic Neuroendocrine Neoplasm with Grade 3: A Japanese Multicenter Pancreatic NEN-G3 Study
2023Open Access
Supplementary Figure Legend from Rb Loss and <i>KRAS</i> Mutation Are Predictors of the Response to Platinum-Based Chemotherapy in Pancreatic Neuroendocrine Neoplasm with Grade 3: A Japanese Multicenter Pancreatic NEN-G3 Study
2023Open Access
How to treat gastrinomas in patients with multiple endocrine neoplasia type1: surgery or long-term proton pump inhibitors?
Surgery Today·2022· 9 citedOpen Access
Phase I/II study of streptozocin monotherapy in Japanese patients with unresectable or metastatic gastroenteropancreatic neuroendocrine tumors
Japanese Journal of Clinical Oncology·2022· 11 citedOpen Access
Nationwide registry for patients with neuroendocrine neoplasm of pancreas, gastrointestinal tract, lungs, bronchi, or thymus in Japan
International Journal of Clinical Oncology·2022· 15 citedOpen Access
Somatostatin Receptor 2 Expression Profiles and Their Correlation with the Efficacy of Somatostatin Analogues in Gastrointestinal Neuroendocrine Tumors
Cancers·2022· 26 citedOpen Access
JNETS clinical practice guidelines for gastroenteropancreatic neuroendocrine neoplasms: diagnosis, treatment, and follow-up: a synopsis
Journal of Gastroenterology·2021· 151 citedOpen Access
page 1 of 25Next →

Frequent Co-authors

Ryuichiro Doi(18), Yutaka Shimada(11), Ryo Hosotani(9), Koji Fujimoto(8), Izumi Komoto(8), Michihiko Wada(7), Yuji Nakamoto(6), Shigeki Arii(6), Eiji Toyoda(5), Masayuki Koizumi(5), Kazuhiro Kami(5), Tomohiko Mori(5), Tetsuhide Ito(5), Masao Tanaka(5), Toshihiko Masui(5), Hisashi Onodera(5), Akira Mori(5), Tatsuya Higashi(5), Junji Konishi(5), Yosuke Hashimoto(5)